Ovid Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.075 million. Net loss was USD 12.41 million compared to USD 14.59 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.21 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.21 a year ago.
For the six months, revenue was USD 0.14116 million compared to USD 1.45 million a year ago. Net loss was USD 25.76 million compared to USD 30.7 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.44 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 0.44 a year ago.